**Supplement Table 1Overview of Clinical Landmark Visits and Additional visits**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **time (months)** | **0** | **Visit X** | **+3** | **+6** | **+12** | **+24** | ***+36*** | ***+48*** | ***+60*** |
| **visit** | **Screening** | **depending on clinical indication** | 1st | 2nd | 3rd | 4th | 5th | 6th | 7th |
| **oral and written Information** | *+* |  |  |  |  |  |  |  |  |
| **written consent** | *+* |  |  |  |  |  |  |  |  |
| **check inclusion-/**  **exclusion criteria** | *+* |  |  |  |  |  |  |  |  |
| **participant characteristics** | *+* |  |  |  |  |  |  |  |  |
| **Info on management program** | *+* | *+* | *+* | *+* | *+* | *+* | *+* | *+* | *+* |
| **questionnaire for App based monitoring** |  |  | *+* |  |  |  |  |  |  |
| **Questionnaire**  **EQ-5D** | *+* |  |  |  |  | *+* | *+* |  |  |
| **venipuncture** | *+* | *(+)* | *+* | *+* | *+* | *+* | *+* | *+* | *+* |
| **complete blood count** | *+* |  |  |  | *+* | *+* | *+* | *+* | *+* |
| **chemistry panel** | *+* |  | *+* | *+* | *+* | *+* | *+* | *+* | *+* |
| **lipid panel** | *+* |  | *+* | *+* | *+* | *+* | *+* | *+* | *+* |
| **HbA1c** | *+* |  | *+* | *+* | *+* | *+* | *+* | *+* | *+* |
| **Aliquots for biomarker analysis** | *+\** |  | *+\** | *+\** | *+\** |  |  |  |  |
| **Clinic BP** | *+* | *+* |  |  |  |  |  |  |  |
| **AOBP** | *+* | *+* | *+* | *+* | *+* | *+* | *+* | *+* | *+* |
| **24BP Measurements** |  |  | + |  | + | + | *+* | *+* | *+* |
| **Home BP in case of HBPM** |  | + | + | *+* | + | + | *+* | *+* | *+* |
| **TTE** |  |  |  | *+\*\*~&* |  | *+\*\** |  |  |  |
| **ECG** |  |  |  | +*\*\** |  | *+\*\** |  |  |  |
| **Urine** | *+* |  | *+* | + | *+* | *+* | *+* | *+* | *+* |
| **Adverse Events** |  |  | + | *+* | *+* | *+* | + | + | + |
| **Hospitalizations and causes** |  |  | *+* | *+* | *+* | *+* | + | + | + |
| **Name and Dosages of Medication**  **during the course of the study** |  | *+* | *+* | *+* | *+* | *+* | + | + | + |
| **Diagnosis of secondary hypertension after 6 months postpartum** |  |  |  | *+* | *+* | *+* | + | + | + |
| **Development of cardiovascular and renal disease** |  |  |  | *+* | *+* | *+* | *+* | *+* | *+* |
| **Development of cardiovascular and renal disease in the setting of gestational hypertension** |  |  |  | *+* | *+* | *+* | *+* | *+* | *+* |
| **Development of cardiovascular and renal disease in the setting of preeclampsia** |  |  |  | *+* | *+* | *+* | *+* | *+* | *+* |
| **Development of cardiovascular and renal disease in the setting of PPHT** |  |  |  | *+* | *+* | *+* | *+* | *+* | *+* |

* \* including NT- pro BNP, Troponin, sFlt-1, PIGF, IL6, PCT, GDF-15

**\*\*** In case of hypertensive heart disease at first echo or persisting hypertension

~ women with postpartum hypertension without persisting hypertension at six months

& matched case controls participants (enrollment planned but yet to be implemented)

## Supplementary Table 2 Cardiac Imaging Control Cohort

|  |  |  |
| --- | --- | --- |
| **time (months)** | **0 months postpartum**  **Control Cohort of the Cardiac Imaging Cohort**  **group 1:**  **women without HDP or PPHT hypertension** | **+3-6 Month postpartum**  **Control Cohort of the Cardiac Imaging Cohort**  **group 2: postpartum normalization of blood pressure** |
| **visit** | **Screening** | 1st /screening for cardiac control group imaging |
| **oral and written Information for TTE** | *+* | *+* |
| **written consent** | *+* | *+* |
| **check inclusion-/**  **exclusion criteria** | *+* | *+* |
| **participant characteristics** | *+* | *+* |
| **clinic BP** | *+* | *+* |

**Newborn Nutrition**

Supplementary Table 3: Breast Feeding

|  |  |
| --- | --- |
| Breastfeeding **n (%)** | 120 (56) |
| Pumping **n (%)** | 81 (38) |

Data presented as n (%)